Immunocore Holdings plc presented three posters about KIMMTRAK®? (tebentafusp-tebn) for the treatment of patients with unresectable or metastatic uveal melanoma (mUM) at the 2024 ASCO (American Society for Clinical Oncology) Annual Meeting. These data showed that treatment benefit for patients with stable disease and any confirmed tumor reduction was similar to patients with partial response.

Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including nine active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. This is the first molecule developed using Immunocore's ImmTAC technology platform designed to reduce and activate T cells to recognize and kill tumor cells. These statements include, but are not limited to, statements regarding the expected clinical benefits of KIMMTRAK, including for mUM patients with stable disease and any confirm tumor reduction, brenetafusp and Immunocore's other product candidates, including RECIST response rate, tumor reduction, including the durability of tumor reduction, ctDNA molecular response, progression free survival and extended overall survival benefit; the expectation that different baseline characteristics and responses to therapy are prognostic factors for benefit from treatment with KIMMTRAK; the benefit of Immunocore's clinical data for physicians treating patients with mUM; the value proposition of Immunocore's products and product candidates, including KIMMTRAK and brenetafusp; and future development plans of Immunocore's products & product candidates, including KimMTRAK and brenETafusp.

These risks and uncertainties include, but are not limited To, the impact of worsening macroeconomic conditions on Immunocore's business, financial position, strategy and anticipated milestones, including Immunocore's ability to conduct ongoing and planned clinical trials; Immunocore's ability to obtain a clinical supply of current or future product candidates or commercial supply of KIMMTRAK or any future approved products, including as a result of health epidemics or pandemics, war in Ukraine, the conflict between Israel, the broader risk of a regional conflict in the Middle East, or global geopolitical tension; Immunocore's ability To successfully expand the approved indications for KIMMTRAK or obtain marketing approval for KIMMTRAK in additional geographies in the future; the delay of any current or planned clinical trials, whether due to patient enrollment delays or otherwise; Immunocore's ability of its product candidates and gain approval of its product candidates on a timely basis, if at all; competition with respect to market market conditions, and other markets, such as a result of the market, and other markets, including including the potential for KIMMTRAK, which is expected to increase the safety and efficacy of its product candidates, including the potential for patients with mUM, which is expected to be in the future.